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Original ArticleSkeletal muscle O-GlcNAc transferase is
important for muscle energy homeostasis and
whole-body insulin sensitivityHao Shi 1,11, Alexander Munk 2,11, Thomas S. Nielsen 2, Morgan R. Daughtry 1, Louise Larsson 2, Shize Li 1,
Kasper F. Høyer 2,3, Hannah W. Geisler 1, Karolina Sulek 2, Rasmus Kjøbsted 4, Taylor Fisher 1,
Marianne M. Andersen 2, Zhengxing Shen 1, Ulrik K. Hansen 2, Eric M. England 1, Zhiyong Cheng 5,
Kurt Højlund 6,7, Jørgen F.P. Wojtaszewski 4, Xiaoyong Yang 8, Matthew W. Hulver 5,9, Richard F. Helm 10,
Jonas T. Treebak 2,*, David E. Gerrard 1,**ABSTRACT
Objective: Given that cellular O-GlcNAcylation levels are thought to be real-time measures of cellular nutrient status and dysregulated O-GlcNAc
signaling is associated with insulin resistance, we evaluated the role of O-GlcNAc transferase (OGT), the enzyme that mediates O-GlcNAcylation,
in skeletal muscle.
Methods: We assessed O-GlcNAcylation levels in skeletal muscle from obese, type 2 diabetic people, and we characterized muscle-speciﬁc OGT
knockout (mKO) mice in metabolic cages and measured energy expenditure and substrate utilization pattern using indirect calorimetry. Whole body
insulin sensitivity was assessed using the hyperinsulinemic euglycemic clamp technique and tissue-speciﬁc glucose uptake was subsequently
evaluated. Tissues were used for histology, qPCR, Western blot, co-immunoprecipitation, and chromatin immunoprecipitation analyses.
Results: We found elevated levels of O-GlcNAc-modiﬁed proteins in obese, type 2 diabetic people compared with well-matched obese and lean
controls. Muscle-speciﬁc OGT knockout mice were lean, and whole body energy expenditure and insulin sensitivity were increased in these mice,
consistent with enhanced glucose uptake and elevated glycolytic enzyme activities in skeletal muscle. Moreover, enhanced glucose uptake was
also observed in white adipose tissue that was browner than that of WT mice. Interestingly, mKO mice had elevated mRNA levels of Il15 in skeletal
muscle and increased circulating IL-15 levels. We found that OGT in muscle mediates transcriptional repression of Il15 by O-GlcNAcylating
Enhancer of Zeste Homolog 2 (EZH2).
Conclusions: Elevated muscle O-GlcNAc levels paralleled insulin resistance and type 2 diabetes in humans. Moreover, OGT-mediated signaling
is necessary for proper skeletal muscle metabolism and whole-body energy homeostasis, and our data highlight O-GlcNAcylation as a potential
target for ameliorating metabolic disorders.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords O-GlcNAc signaling; Type 2 diabetes; N-acetyl-D-glucosamine; Tissue cross talk; Epigenetic regulation of Il15 transcription; Insulin
sensitivity1. INTRODUCTION
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GlcNAcase (OGA), respectively, serve as an integrated cellular nutrient
sensor. First, the amount of O-GlcNAc-modiﬁed cellular proteins in-
creases in response to elevated nutrient and energy availabilities [2].
Second, the activity of key signaling molecules in the canonical insulin
signaling pathway, such as the b subunit of the insulin receptor, IRS1,
IRS2, p85 and p110 subunits of PI3K, PDK1, and Akt is generally
inhibited by OGT-dependent O-GlcNAcylation [3e7]. Third, transcrip-
tion co-factors such as FOXO1 and PGC-1a, which are master regu-
lators of gluconeogenesis and lipid metabolism, respectively, are
targeted by OGT which results in the stabilization of the proteins [8].
Fourth, OGT and the energy sensor AMP-activated protein kinase
(AMPK) physically interact and mutually modify each other’s function
and/or localization [6,9]. Accordingly, dysregulation of cellular O-
GlcNAcylation may be involved in the pathogenesis of a number of
metabolic diseases, including obesity and type 2 diabetes [10,11]. This
is evidenced by ﬁndings showing critical roles of O-GlcNAcylation
status in AgRP and a-CaMKII positive neurons for maintaining whole
body energy balance in mice [12,13].
Skeletal muscle is an important metabolic tissue and plays essential
roles in locomotion and thermogenesis, both having signiﬁcant impacts
on global glucose metabolism and insulin sensitivity [14e17]. Skeletal
muscle utilizes a highly complex set of intercalated and coordinated
signaling mechanisms to respond to altered environmental nutritional
cues [18e20]. Previous studies have suggested that dysregulated O-
GlcNAc signaling in skeletal muscle is associated with the develop-
ment of several metabolic diseases. For example, over-expression of
OGT in muscle and adipose tissue causes insulin resistance and im-
pairs glucose transport, respectively [21,22]. In addition, over-
expression of OGA, which eliminates O-GlcNAcylation, impairs
myogenesis and induces muscle atrophy [23,24]. These ﬁndings
suggest that O-GlcNAcylation may be part of a complex signaling
mechanism within skeletal muscle that is responsible for monitoring
cellular nutrient availability and conveying this information to down-
stream targets to induce metabolic adaptation. Apart from the studies
mentioned above, however, the precise role of O-GlcNAcylation in
skeletal muscle remains largely unexplored. Herein, we show that
skeletal muscle from type 2 diabetic humans has elevated O-GlcNA-
cylation levels compared with matched controls. Moreover, we show
that knockout of OGT in skeletal muscle in mice causes alterations of
muscle metabolism that improves whole-body insulin sensitivity and
increases energy expenditure. We propose a mechanism whereby lack
of OGT results in perturbed regulation of Il15 expression, which sub-
sequently drives the observed phenotype.
2. MATERIALS AND METHODS
2.1. Human samples
Human skeletal muscle samples were obtained from a previous study
[25]. In short, muscle samples were obtained from the vastus lateralis
muscle (Bergström needle biopsy) before and after a 4-hour eugly-
cemic hyperinsulinemic clamp (40 mU * m2 * min1) under local
anesthesia. Muscle biopsy samples were quickly blotted free of blood
and frozen in liquid nitrogen. Muscle lysates were prepared from
freeze-dried muscle dissected free of visible blood, fat, and connective
tissue and homogenized as previously described [26]. Lysates were
collected from the supernatant of homogenates centrifuged for
20 min at 16,000 g and 4 C. Total protein content in lysates was
analyzed by the bicinchoninic acid method (ThermoFisher Scientiﬁc).
Muscle lysates were prepared in Laemmli buffer and heated for
10 min at 96 C after which equal amounts of protein were separatedMOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comby SDS-PAGE. Proteins were transferred to PVDF membranes and
incubated with the indicated antibodies.
2.2. Animals
Mice were generated and experiments performed at either the Novo
Nordisk Foundation Center for Basic Metabolic Research, University of
Copenhagen, or Virginia Polytechnic Institute and State University.
Muscle speciﬁc Ogt deletion was achieved by breeding HSACre/þ;Ogt-
LoxP/Y (JaxMice, strain: B6.Cg-Tg(ACTA1-cre)79Jme/J) males with
OgtLoxP/LoxP females to generate HSAþ/þ;OgtLoxP/Y (WT) and HSACre/
þ;OgtLoxP/Y (mKO) mice. Inducible muscle-speciﬁc OGT knockout mice
were generated by breeding HSA-rtTA/TRE-Cre (JaxMice, strain B6;
C3-Tg(ACTA1-rtTA,tetO-Cre)102Monk/J) male mice with OgtLoxP/LoxP
females. All procedures were approved by the Danish Animal Experi-
ments Inspectorate and complied with the European convention for
protection of vertebrate animals used for scientiﬁc purposes (EU
Directive 2010/63/EU for animal experiments), or they were approved
by Institutional Animal Care and Use Committee of the Virginia Poly-
technic Institute and State University and complied with the National
Institutes of Health guidelines (NIH Publications No. 8023). Mice were
group-housed in an enriched environment with a 12 h light:12 h dark
cycle with ad libitum feed (#1310, Altromin for mice at University of
Copenhagen, and #2918, Envigo for mice at Virginia Polytechnic Insti-
tute and State University) and water in a temperature-controlled
(22 C  1 C) room. Mice used for HFD study were fed Teklad ro-
dent diets (#TD.06414, Envigo) with 60% calories coming from fat. The
fatty acid proﬁle (% of total fat) is as follows: 37% saturated, 47%
monounsaturated, 16% polyunsaturated. The control diet was the
standard chow (#2918, Envigo). Mice were fed HFD or normal chow
from 4 weeks of age for the indicated weeks.
2.3. Whole body metabolic assessment
Whole body metabolic phenotyping was performed at Virginia Tech
Metabolic Phenotyping Core using the TSE LabMaster Indirect Calo-
rimetry System. For acclimation purpose, mice were housed in a mock
LabMaster cage for one week before they were transferred to
recording cages to measure locomotor activity and indirect calorimetry.
Mice were fed ad libitum during the indicated experimental period.
Cage activity, energy expenditure normalized to lean body mass, and
respiratory exchange rates were recorded for a 48-h period at the
interval of 20 min. Whole body composition was measured by MRI
(Minispec Whole Body Composition Analyzer, Bruker). Rectal temper-
ature was recorded at 4PM using an ETI Microtherma 2 Type T ther-
mometer (ThermoWorks). The probe was inserted into the anal ducts
of the mice (around 2 cm) when animal was awake in the absence of
anesthesia.
2.4. Histology and immunohistochemistry
Muscle, WAT, liver, and pancreas were collected from WT and mKO
mice and ﬁxed in 10% neutral buffered formalin (0.4% sodium
phosphate monobasic, 0.65% sodium phosphate dibasic, 10%
formalin, pH 6.8) overnight. The tissues were then washed twice in
70% ethanol, and parafﬁn-embedded. For H&E staining, tissue sec-
tions were de-parafﬁnized with two exchanges of xylene, rehydrated in
100%, 95%, and 70% ethanol respectively. After a brief wash in water,
sections were stained in Harris hematoxylin for 8 min, washed in
running water for 1 min, soaked in 0.2% ammonia water for 1 min.
After washing in running water for 5 min, the tissue sections were
rinsed in 95% ethanol for 10 s. Sections were then counterstained with
eosin solution for 30 s, dehydrated in 95% ethanol, 100% ethanol, andccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 161
Original Articlexylene, and mounted for microscopy. For immunohistochemical
staining, parafﬁn-embedded sections were de-parafﬁnized and re-
hydrated, and antigen was retrieved by heating the sections in
boiling sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20,
pH 6.0) for 30 min. After cooling down at room temperature for 20 min,
tissue sections were blocked in 5% goat serum for 1 h at room
temperature before applying primary antibodies anti-UCP1 (#10983
Abcam) or anti-succinate dehydrogenase (#14715 Abcam), 1:200
diluted in 5% goat serum. After incubation in the primary antibody
overnight at 4 C, sections were washed in 1 x PBS three times with
5 min each. The sections were then incubated in Alexa Fluor 488
conjugated goat anti rabbit IgG (#A-11078 ThermoFisher Scientiﬁc) or
Alexa Fluor 555 goat anti mouse IgG (#A-21424 ThermoFisher Sci-
entiﬁc) highly cross-absorbed antibodies, respectively, for 1 h at room
temperature, washed in PBS, and mounted in ﬂuorescent mounting
medium for microscopy. Images were taken using a Nikon ECLIPSE Ti-
E ﬂuorescent microscope (Nikon Instruments).
2.5. Ex vivo EDL and soleus muscle contractility assay
Isolated soleus and extensor digitorum longus (EDL) muscles from male
mice (12e16 weeks of age) were used for muscle contractility assays.
Muscles were incubated at 30 C in oxygenated (95% O2 and 5%
CO2) physiological salt solution as previously described in [27] for
Figure 1MeP and in [28] for Figure 1QeT. The buffer was continuously
oxygenated with 95% O2 and 5% CO2 during the incubation period and
maintained at 30 C. For results shown in Figure 1MeP, muscles were
set to an initial resting tension of 10 mN (optimal length, L0; 300B,
Aurora Scientiﬁc) and maintained by a stepper motor. Dynamic Muscle
Control software (DMC Version 4.1.6, Aurora Scientiﬁc) was used to
control the force and position inputs of the servomotor arm and the
stepper motor. For results shown in Figure 1MeO, the stimulated
muscle was subjected to 3 isometric twitches and two tetani (150 Hz)
each separated by 1 min. For Figure 1P, the muscle was subjected to a
force frequency protocol consisting of 6 stimulations of increasing fre-
quency (1, 30, 50, 80, 100, and 150 Hz), one min apart. For results
shown in Figure 1QeT, muscles were incubated in a muscle strip
myograph system (820MS, DMT, Denmark) at a 5e6 mN tension.
Muscles were stimulated to contract using the following protocol:
stimulus frequency 100 Hz; stimulus width 0.2 ms; stimulus train
duration 1 sec train every 15 sec. The total stimulation protocol was
9 min.
2.6. Hyperinsulinemic euglycemic clamp experiments
The hyperinsulinemic euglycemic clamp was performed in conscious,
unrestrained male mice at 17e19 weeks of age as previously
described [29]. For the surgical catheterization, mice were anes-
thetized with isoﬂurane (2.5% for induction, 1.5% for maintenance).
Lidocain (7 mg/kg; Xylocain, AstraZeneca, Sweden) and Carprofen
(10 mg/kg; Rimadyl, Pﬁzer, USA) were administered preoperatively for
analgesia. All surgical procedures were conducted using strictly
aseptic techniques. The carotid artery and jugular vein were cannu-
lated and the catheters were externalized on the back (caudal to the
scapulae) with a dual channel vascular access button (Instech, PA,
USA). After surgery, the catheters were locked with heparinized saline
(200 U/mL) and the animals recovered for 6e7 days. Body weight was
recorded before and 24 h after the operation and on the day of the
clamp. The inclusion criteria following surgery were a weight loss of
less than 10% and a hematocrit above 35% by day 6e7. All mice
fulﬁlled these criteria. On the day of the clamp experiment, mice were
fasted for 5 h starting at 7:30 AM (t¼ 300 min) by placing them in a
clean cage with bedding and nesting material, and free access to162 MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH.water. At t ¼ 120 min the mice were placed in a new cage of
w20  20 cm, the catheters were ﬂushed with heparinized saline
(10 U/mL) and the mice were connected to the infusion lines. A tracer
equilibration period was started at t ¼ 90 min by infusion of a
1.2 mCi priming dose of [3-3H]glucose (Product no. NET331C005 MC;
Perkin Elmer, USA) followed by a constant 0.04 mCi/min infusion of [3-
3H]glucose for 90 min. Blood samples were collected for the
assessment of baseline hematocrit level (40 mL) as well as basal
glucose levels and turnover rates at t ¼ 15 min (50 mL) and 5 min
(100 mL), respectively. The clamp was initiated at t ¼ 0 min with
continuous infusions of human insulin (4 mU/kg/min; Actrapid, Novo
Nordisk, Denmark) and washed red blood cells obtained from a donor
mouse to compensate for the blood loss due to repeated sampling
(5 mL/min of 50% RBC in 10 U/ml heparinized saline). Blood glucose
was measured every 10 min (Contour XT; Bayer, USA) and euglycemia
was maintained by adjusting a variable infusion of 50% glucose
containing 0.06 mCi/mL of [3-3H]glucose tracer. Between t ¼ 80 and
t ¼ 120 min blood samples (50e100 mL) were collected in 10 min
intervals and processed for determination of [3-3H]glucose speciﬁc
activity. At t¼ 110 min hematocrit was measured again to ensure that
hematocrit levels were stable. At t¼ 120 min a 12 mCi bolus of 2-[1e
14C]-deoxy-D-glucose (Product no. NEC495250UC; Perkin Elmer, USA)
was injected and blood samples were collected at t ¼ 122, 125, 135,
145, and 155 min, respectively. These samples were processed for
determination of 2-[1e14C]-deoxy-D-glucose speciﬁc activity. After
the ﬁnal blood sample, mice were euthanized with a lethal dose of
pentobarbital and tissues were collected and snap-frozen in liquid
nitrogen. The tissues were processed for determination of 2-[1e14C]-
deoxy-D-glucose speciﬁc activity in order to calculate tissue-speciﬁc
glucose uptake.
2.7. Clamp sample processing and calculations
Plasma samples were deproteinized with Ba(OH)2 and ZnSO4, and
aliquots of each supernatant were transferred to 2 scintillation vials. To
determine plasma [3-3H]glucose, one of the aliquots was dried and
resuspended in MilliQ water to remove 3H2O and the other was
counted directly (Hidex 300 SL). Supernatants for 2-[1e14C]-deoxy-D-
glucose determinations were counted directly. Total plasma glucose
concentration was determined by adding a reaction mix (200 mM
TriseHCl, 500 mM MgCl2, 5.2 mM ATP, 2.8 mM NADP, and 148 mg of
a hexokinase and G6PDH mixture (Roche, Germany) pH 7.4) to each
sample and measuring absorbance at 340 nm. Parameters related to
glucose turnover rates (Ra, Rd, endoRa, glycolysis) were calculated as
previously described [30]. Tissues were homogenized in ice-cold lysis
buffer (pH 7.4, 10% glycerol, 1% IGEPAL, 50 mM Hepes, 150 mM
NaCl, 10 mM NaF, 1 mM EDTA, 1 mM EGTA, 20 mM sodium pyro-
phosphate, 2 mM sodium orthovanadate, 1 mM sodium-
pyrophosphate, 5 mM nicotinamide, 4 mM Thiamet G, and protease
inhibitors (SigmaFast)). Aliquots of each crude homogenate were
transferred to two 1.5 mL tubes and deproteinized with 4.5%
perchloric acid or Ba(OH)2 þ ZnSO4. Supernatants were transferred to
scintillation vials and counted to determine 2-[1e14C]-deoxy-D-
glucose content. Tissue-speciﬁc glucose uptake rates were calculated
as described previously [31].
2.8. Insulin and glucose tolerance test
Mice were fasted for four hours before insulin tolerance test
(ITT). Bovine insulin (Sigma) was prepared in sterile saline and intra-
peritoneally injected at the dosage of 1 U/kg body weight. Blood
glucose level was measured at 0, 15, 30, 60, 90, and 120 min after
insulin injection using OneTouch Ultra2 test strip and glucometer. ForThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Mice lacking OGT in skeletal muscle exhibit reduced fat mass but normal skeletal muscle morphology and contractility. (A) O-GlcNAc levels in human skeletal
muscles of lean, obese, and type 2 diabetic individuals at basal (B) and after a hyperinsulinemic euglycemic clamp (Insulin (I)). Lane intensities were quantiﬁed between 15 and
300 kDa. Sample size of 8e10 people per group. Data are mean  SEM and analyzed by two-way repeated measures ANOVA; ** indicates p < 0.01. (B) OGT, (C) O-GlcNAc, and
(D) OGA immunoblotted in tibialis anterior (TA), soleus, and extensor digitorum longus (EDL) muscles from WT and mKO mice (n ¼ 4). (E) Body weights of WT and mKO mice
measured at 6, 9, 12, 16, and 30 weeks of age (n ¼ 6e10). (FeH) Body composition: fat percentage (F), lean percentage (G), and muscle weights (H) of TA, soleus, and EDL in
16-week-old WT and mKO mice (n ¼ 10). (I) Images comparing abdominal, inguinal (IngW) and epididymal (EpiW) white adipose tissue (WAT) depots from WT and mKO mice. (J)
Quantiﬁcation of adipose tissue weights expressed as percentage (%) body weight (n ¼ 10). (K) Representative micrographs of H&E stained sections from epididymal (EpiW) and
inguinal (IngW) white adipose tissues (WAT) of WT and mKO mice. Scale bar, 100 mm. The relative size of adipocytes in the EpiW and IngW of mKO mice was expressed as a
percentage of WT (n ¼ 10). (L) Immunoreactive uncoupling protein 1 (UCP1) in IngW of WT (left) and mKO (right) mice. Scale bar, 100 mm. (MeO) EDL muscle single-twitch
contraction force (M), time-to-half relaxation tension (T1/2R; n ¼ 10) (N), and time to peak of tension (n ¼ 10) (O). (P) EDL muscle contractile force in response to increased
stimulation frequency (n ¼ 10). Data normalized to force at 150 Hz. (Q,R) First force train at 100Hz, 1 sec duration in soleus (Q; n ¼ 5), and fatigue-ability measured as force
produced over consecutive force trains at 100 Hz, 1 sec duration in soleus (R; n ¼ 5). (S,T) First force train at 100 Hz, 1 sec duration in EDL (S; n ¼ 5), and fatigue-ability
measured as force produced over consecutive force trains at 100 Hz, 1 sec duration in EDL (T; n ¼ 5). Data in B-T are means  SEM from 16-week-old male mice.
*p < 0.05; **p < 0.01; ***p < 0.001 compared with WT mice.
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Original Articleglucose tolerance test (GTT), mice were fasted overnight (16 h) before
the experiment, glucose was intraperitoneally injected at the dosage of
2 g/kg body weight, and blood collection and measurement were the
same as ITT.
2.9. Skeletal muscle mitochondrial isolation
Isolation of mitochondria from skeletal muscle was performed as
previously described [32]. Brieﬂy, quadriceps femoris and gastrocne-
mius muscles were collected in buffer containing 67 mM sucrose,
50 mM Tris/HCl, 50 mM KCl, 10 mM EDTA/Tris, and 10% BSA (Sigma).
Before homogenization, muscle samples were minced with scissors,
and digested in PBS containing 0.05% trypsin (Invitrogen) and 10 mM164 MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH.EDTA (Sigma) for 30 min. Muscles were homogenized with a Teﬂon
pestle at the speed of 1,600 rpm and mitochondria were isolated by
differential centrifugation.
2.10. Respirometry of isolated mitochondria
Mitochondrial respiration was measured using an XF24 extracellular
ﬂux analyzer (Seahorse bioscience) as previously described [33].
Freshly isolated mitochondria were seeded at 5 mg per well in a
Seahorse XF Cell Culture Microplate. Mitochondria were suspended in
a sucrose/mannitol solution containing pyruvate (10 mM) and malate
(5 mM). Mitochondria were mixed for 25 sec before the measurement
cycles. Oxygen consumption rates (OCRs) at basal conditions (state 2),This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original ArticleADP (5 mM) stimulation (state 3), ADP exhaustion (state 4), oligomycin
(2 mM) induction (state 4), and FCCP (0.3 mM) induction were
measured to assess mitochondrial oxidative capacity. All experiments
were performed at 37 C.
2.11. Fatty acid oxidation and PDH activity assay
Fatty acid oxidation was assessed in muscle homogenates as previ-
ously described [34]. Brieﬂy, [1e14C]-palmitic acid (Perkin Elmer) was
used as the substrate, 14CO2 production and
14C-labeled acid-soluble
metabolites were measured by liquid scintillation counting. Pyruvate
dehydrogenase (PDH) activity was assayed using [1e14C]-pyruvate as
substrate, enzyme catalyzed release of 14CO2 was counted to reﬂect
PDH enzyme activity.
2.12. Citrate synthase (CS) and malate dehydrogenase (MDH)
activity assay
CS and MDH activities were determined as previously described [34].
CS activity was determined by the rate of DNTB reduction upon
exposure to acetyl CoA, the product (TNB) is measured spectropho-
tometrically at 412 nm. Malate dehydrogenase (MDH) activity was
determined by the rate of NADH oxidation in the presence of oxalo-
acetate and measured at 340 nm.
2.13. Western blot analyses
Skeletal muscle samples used in Figures 7 and 8 were lysed in RIPA
buffer (in mM: 200 NaCl, 20 Tris-Cl at pH 8.0, 1 EDTA, 1 EGTA, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 2.5 sodium
pyrophosphate, 1 b-glycerol phosphate, 1 Na3VO4, and protease in-
hibitor cocktail (Sigma) and protein concentration was determined
using a Bicinchoninic Acid (BCA) Protein Assay kit (Pierce). All other
tissue samples were processed using steel bead homogenization
(Tissue Lyser II, Qiagen) in ice-cold lysis buffer (pH 7.4; 10% glycerol;
1% IGEPAL; Hepes, 50 mM; NaCl, 150 mM; NaF, 10 mM; EDTA, 1 mM;
EGTA, 1 mM; sodium pyrophosphate, 20 mM; sodium orthovanadate,
2 mM; sodium-pyrophosphate 1 mM; nicotinamide 5 mM; Thiamet G
4 mM and protease inhibitors (SigmaFast, Sigma Aldrich) according to
manufacturer’s instructions). Equal amounts of protein were separated
using SDS-PAGE and transferred to PVDF membranes. Antibodies used
for Western blot analyses were: anti-OGT (#SAB2101676 Sigma), anti-
O-GlcNAc (#2739 Abcam), anti-ATP synthase b subunit (#A-21351
ThermoFisher Scientiﬁc), anti-succinate dehydrogenase A subunit
(SDHA) (#14715 Abcam), OGT (#5368 CST), O-GlcNAc (CTD110.6
#9875 CST), OGA (#124807 Abcam), Hexokinase II (#2867 CST), PFK1
(#166722 Santa Cruz Biotechnology (SCBT)), PDH (#C54G1 CST), PDH
pS293 (#ABS204 Millipore), PDH pS300 (#ABS194 Millipore), ACC
pS79/257 (#07e300 Millipore), Insulin receptor b (#3025 CST), IRS1
(#23822 CST), AKT 1/2/3 (#9272 CST), AKT pT308 (#9275 CST), AKT
pS473 (#9271 CST), AKT1 (#5298 SCBT), TBC1D4 (#07e741 Milli-
pore), TBC1D4 pS711 (Custom), TBC1D4 pS324 (Custom), ATGL
(#2138 CST), HSL (#4107 CST), HSL pS563 (#4139 CST), GFAT1
(#125069 Abcam), GLUT4 (#PA1-1065 Thermo Fisher).
2.14. Metabolomics analysis
OGT mKO (n¼ 10) and WT (n¼ 8) mice underwent a hyperinsulinemic
euglycemic clamp. Following this procedure muscle samples were
collected, frozen in liquid nitrogen, and stored at 80 C. Whole
muscle sample was pulverized under liquid nitrogen and 30  3 mg
(exact mass was noted) underwent metabolomics analysis. Methanol
at concentrations 50%, 80%, and 100% with water was used for the
metabolites extraction from the muscles. Metabolites were proﬁled
using liquid chromatography combined with mass spectrometry.166 MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH.Following data bucketing and normalization, student t-test with false
discovery rate analysis was performed. Detailed metabolomics anal-
ysis is available in the Supplementary Materials.
2.15. Quantitative RT-PCR
Directzol RNA Miniprep Kit (Zymo Research) was used to extract total
RNA from skeletal muscle or adipose tissue. High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientiﬁc) was used to
perform reverse transcription. Fast SYBR Green Master Mix (Thermo
Fisher Scientiﬁc) and 7500 Fast Real Time PCR System (Thermo Fisher
Scientiﬁc) were used to carry out qPC reaction. Primers used in this
paper were published elsewhere [35]. Quantiﬁcation was performed
using DDCT method.
2.16. Muscle extract collection and SVF cell isolation and
differentiation
Muscle extracts were collected by isolating both WT and mKO
gastrocnemius muscles and placing them in DMEM for 2 h at 37 C
with 80rpm agitation. The conditioned media were collected, and
protein concentration determined. The conditioned media were mixed
with SVF cell differentiation media to assess the effect of muscle
extracts on SVF cell differentiation. For SVF cell isolation, inguinal
WATs were collected from adult C57BL/6J mice, minced, and trans-
ferred to digestion medium (Ham’s F10 medium containing 500 units
per mL collagenase II 10% horse serum, 1% penicillin/streptomycin,
and 0.1% gentamycin) for 1 h at 37 C with 80 rpm agitation. To stop
the digestion, complete medium (DMEM containing 10% FBS and 1%
penicillin/streptomycin) was added followed by triturating 20 times to
generate a homogenous mixture. The cells were centrifuged at 450 g
for 5 min, and the supernatant was discarded. The pellet containing
the SVF cells was re-suspended in complete medium, ﬁltered through
a 40 mM cell strainer, and the throughput was centrifuged. The pellet
was re-suspended in complete medium and plated onto a 15 cm
collagen-coated dish. Two hours later the cells were washed with PBS
to remove alternate cell types. After reaching conﬂuence, the cells
were re-plated on 12-well collagen-coated dishes at 1,000 cells per
mm2. Twenty-four hours after plating, cells were changed to induction
medium (complete medium containing 5 mg/ml insulin, 1 nM 3,30,5-
triiodo-L-thyronine, 125 mM indomethacin, 2 mg/mL dexamethasone,
and 0.5 mM 3-isobutyl-1-methylxanthine), mixed with WT and mKO
muscle extracts in the presence or absence of IL15 antibody. After
72 h the cells were changed to maintenance medium (complete
medium containing 5 mg/mL insulin and 1 nM 3,30,5-triiodo-L-thyro-
nine) with muscle extracts with or without IL15 antibody. After 96 h,
the cells were ﬁxed with 10% formalin, stained with Oil Red O, and
imaged.
2.17. Immunoprecipitation (IP)
For IP, gastrocnemius muscles were isolated from mice, minced and
homogenized in NP40 lysis buffer (50 mM TriseHCl, 1% NP40,
150 mM NaCl, 1 mM EDTA) in the presence of 1 mM PMSF, 1 mg/mL
leupeptin, 1 mg/mL aprotinin, 1 mg/mL pepstatin, 1 mM Na3VO4, 1 mM
NaF, and 40 mM PUGNAc. Antibodies against O-GlcNAc (Abcam, RL2)
and EZH2 (Abcam) were incubated with 500 mg of total protein
overnight at 4 C with agitation, respectively. The immune complexes
were incubated with protein A beads, washed, and eluted using
sample buffer for further immunoblotting analysis.
2.18. Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described [36]. The precipitated
chromatin was puriﬁed and DNA was quantiﬁed using quantitative RT-This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original ArticlePCR. The ChIP-grade antibodies against O-GlcNAc, EZH2, and
H3K27me3 were bought from Abcam. Primers for the Il15 promoter
were as follows: forward GCC TGT TTG GGA ACA GTA AAC; reverse
CAA CTT AAA GAT GCT GCC TTA CC.
2.19. Statistical analyses
Results are presented as means  SEM. Levene’s test for homoge-
neity of variances was performed prior to statistical comparisons be-
tween groups. Data were log10 transformed if Levene’s test was
signiﬁcant. In all cases, this was sufﬁcient to obtain equal variance.
Comparison between two groups was performed using Student’s t test
with two-tailed distribution. For multiple-group comparisons, one-way
and two-way ANOVAs were used to test for no differences among the
group means. In case of signiﬁcant interactions, Tukey’s multiple
comparison test was performed post hoc. p < 0.05 was considered
statistical signiﬁcant.168 MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH.3. RESULTS
3.1. Type 2 diabetes is associated with elevated O-GlcNAcylation
levels in skeletal muscle
We hypothesized that increased blood glucose concentrations
observed in type 2 diabetic people would result in elevated O-
GlcNAcylation of proteins in skeletal muscle. Vastus lateralis muscle
biopsies were obtained before and after a 4-hour hyperinsulinemic
euglycemic clamp from well-matched lean, obese, and obese, insulin
resistant type 2 diabetic patients [25]. We found that ‘global’ O-
GlcNAcylation levels were signiﬁcantly increased in type 2 diabetic
people independent of insulin compared with controls (Figure 1A).
Moreover, we quantiﬁed protein abundance of key O-GlcNAc-related
enzymes OGT, OGA, and glutamine:fructose-6-phosphate amido-
transferase (GFAT), all of which showed no difference in total protein
abundance (Supplementary Figure 1AeC). These data show that O-This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original ArticleGlcNAcylation increases in muscle tissue with blood glucose levels
and suggest that skeletal muscle OGT may be involved in the
development of insulin resistance and type 2 diabetes in humans.
These data prompted us to investigate further the role of OGT in
skeletal muscle.
3.2. Mice lacking muscle OGT have a lean phenotype
To assess the role of OGT in skeletal muscle, we bred male mice
harboring Cre recombinase the expression of which was driven by the
human skeletal a-actin promoter (HSA-Cre mice) with Ogt ﬂoxed ho-
mozygous female mice to generate muscle-speciﬁc hemizygous OGT
knockout (mKO) and wild type (WT) mice. OGT was ablated in skeletal
muscle as evidenced by the lack of OGT protein in tibialis anterior (TA),
soleus, and extensor digitorum longus (EDL) muscle of mKO mice,
(Figure 1B). Consequently, O-GlcNAcylation levels in these muscles
were greatly reduced (Figure 1C). Moreover, levels of O-GlcNAcase
(OGA) were signiﬁcantly reduced in all three muscles (Figure 1D),
suggesting a corresponding compensatory mechanism of the recip-
rocal cellular O-GlcNAcylation. Additionally, and as expected, we found170 MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH.no difference in OGT protein levels in the heart (Supplementary
Figure 2A). By 12 weeks of age, mKO mice had similar body
weights compared with WT controls (Figure 1E). However, after 12
weeks of age, mice lacking muscle OGT were signiﬁcantly smaller than
WT mice (Figure 1E), yet no differences in muscle cross sectional area
or muscle ﬁber number were noted in the soleus or EDL muscles
(Supplementary Figure 2BeD). This reduction in body mass was
associated with a reduction in whole-body fat accumulation
(Figure 1F), but not lean mass (Figure 1G) at 16 weeks of age in mKO
compared to their WT littermates. Consistently, muscle weights of TA,
soleus, and EDL did not differ among genotypes at 16 weeks of age
(Figure 1H). Fat depots, including the anterior subcutaneous white
adipose tissue (AsW), inguinal white adipose tissue (IngW), and
epididymal white adipose tissue (EpiW), but not the brown adipose
tissue (BAT), were greatly reduced in mKO compared to those of WT
mice (Figure 1I,J). This reduction in fat mass was partly due to smaller
adipocytes (Figure 1K) and a corresponding browning of white adipose
tissue as assessed by immunohistochemistry analysis for UCP1
(Figure 1L). No differences in Ucp1 gene expression in BAT wereThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 8: OGT knockout results in augmented Interleukin-15 production in skeletal muscle. (A) Expression of myokines in the gastrocnemius muscles of WT and mKO mice
fed HFD for 22 wks (B) IL-15 mRNA expression in skeletal muscles from clamped mice (n ¼ 8e10, 18-week-old male mice). (C) Serum IL-15 levels in WT and mKO mice fed HFD
for 22 wks (n ¼ 10). (D) Oil red-O staining of cultured stromal vascular fraction cells isolated from mouse IngW and induced to differentiate in the presence or absence of
gastrocnemius muscle extracts from WT (top row) and mKO (bottom row) mice with (right) or without (left) IL15 neutralizing antibodies. Scale bar, 1 mm. (E) Expression of lipogenic
genes in IngW (n ¼ 10). (F) Immunoprecipitation was performed using anti-EZH2 and anti-O-GlcNAc antibodies respectively, and immunoblotted with O-GlcNAc and EZH2
antibodies respectively. (GeI) Chromatin immunoprecipitation using antibodies against O-GlcNAc (G), EZH2 (H), and H3K27me3 (I), respectively. Quantitative RT-PCR was used to
quantify IL-15 promoter sequence as detailed in Methods. *p < 0.05, **p < 0.01, ***p < 0.001 compared to WT or corresponding antibody-treated samples.observed (Supplementary Figure 2E). To assess whether muscle
function was impacted by OGT ablation, we assessed muscle con-
tractile properties. No differences in single-twitch force (Figure 1M),
half-relaxation time of the single twitch (Figure 1N), or time to peak
tension (Figure 1O) were observed between WT and mKO EDL mus-
cles. Muscle force of EDL during tetanic contractions increased
gradually with stimulation frequency, but no differences were noted
between genotypes (Figure 1P). Moreover, we did not observe any
differences between WT and mKO soleus and EDL muscles in terms of
force production during a single tetanic contraction or fatigue-ability
during repeated tetanic contractions (Figure 1QeT). Collectively,
these data show that mKO mice have a lean phenotype due to a
reduction in whole-body fat mass, yet no functional alterations in
muscle growth, development, or function were identiﬁed.MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH. This is an open a
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To investigate the mechanism of the lean phenotype in mice lacking
OGT in skeletal muscle, we assessed whole body energy metabolism
by indirect calorimetry over a period of 48 h. Interestingly, we found
that mKO mice were less active than WT mice in both light and dark
phases of the day (Figure 2A,B). While mKO mice had less cage ac-
tivity, their energy expenditure normalized to lean body mass was
greater than WT mice (Figure 2C,D). Additionally, mKO mice had a
higher respiratory exchange ratio (RER) compared to WT mice
(Figure 2E,F), indicating that these mice have greater reliance on
carbohydrates than fat for energy production. Food intake did not differ
between genotypes (Figure 2G), but water consumption was greater in
the mKO mice (Figure 2H). Given mKO mice weigh less than WT mice
from 3 months of age (Figure 1E) and have less cage activityccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 171
Original Article(Figure 2A,B), we hypothesized that ablation of muscle OGT caused an
increase in energy expenditure in the form of heat production. Higher
rectal temperatures were indeed noted for mKO mice compared to that
of WT mice (Figure 2I). Taken together, these ﬁndings suggest that
skeletal muscle OGT and O-GlcNAcylation may regulate muscle energy
metabolism, which may affect activity and whole body energy balance.
3.4. Lack of OGT in skeletal muscle affects glucose homeostasis,
insulin signaling, and whole-body insulin sensitivity
To determine how ablation of OGT in skeletal muscle affects the ability
of muscle to handle energy substrates, we performed a hyper-
insulinemic euglycemic clamp to assess whole-body insulin sensitivity.
Mice were clamped at 6 mM of blood glucose (Figure 3A,B), and mKO
mice displayed a profound increase in glucose infusion rate (GIR)
(Figure 3C,D). Interestingly, insulin levels at basal and during the clamp
were signiﬁcantly reduced in the mKO compared to WT mice
(Figure 3E). We found glucose uptake was markedly increased in TA,
gastrocnemius, and triceps from mKO mice compared to WT mice, yet
the differences were not consistent among muscles as there was no
difference in glucose uptake in the EDL, quadriceps, and soleus
muscles between genotypes (Figure 3F). In white adipose tissues,
there were noticeable increases in glucose uptake in EpiW and IngW
(Figure 3G). In contrast, brown adipose tissue (BAT) displayed a 50%
decrease in glucose uptake, and there was no change of glucose
uptake in heart or brain (Figure 3H). Glycogen levels in the liver after
the clamp was increased in mKO mice, but skeletal muscle glycogen
levels were not different between genotypes (Figure 3I). However, liver
glycogen of the non-insulin-stimulated mKO cohort, used as blood
donors for the clamped mice, was also increased (Figure 3J). While our
data suggest that skeletal muscle and white adipose tissue are mainly
responsible for the enhanced GIR in the mKO mice, the liver may play
an important role in whole-body glucose utilization in these mice. In
clamped gastrocnemius muscle, in which glucose uptake was
increased, both total Akt protein abundance and Akt phosphorylation at
T308 and S473 were increased in mKO mice compared to WT litter-
mates (Figure 3K). Total Akt1 protein levels did not differ between
genotypes (Figure 3L), suggesting that the enhanced level of Akt in the
mKO mice is due to increased Akt2 abundance. Interestingly, the
difference in Akt signaling between genotypes was not associated with
differences in TBC1D4 phosphorylation status (Figure 3M); however,
GLUT4 levels were signiﬁcantly increased in the gastrocnemius muscle
of the mKO mice compared to WT mice (Figure 3N). These data
suggest that differences observed in whole body insulin sensitivity may
not be due to classical insulin signaling events in skeletal muscle but
may still be mediated by a larger increase in GLUT4 at the plasma
membrane at a given insulin concentration.
3.5. Loss of OGT alters global muscle metabolism
Because loss of OGT in skeletal muscle resulted in increased energy
expenditure and whole-body insulin sensitivity, we explored metabolic
changes in skeletal muscle that could explain the lean phenotype of
mKO mice. To this end, we investigated muscle metabolite levels in the
gastrocnemius of clamped mice. Using an LC/MS-based metabolomics
analysis, we identiﬁed 41 metabolites that differed between genotypes
(Figure 4A). Of these, fructose 1,6 biphosphate (Fru-1,6P) and phos-
phoenolpyruvate (PEP) were reduced by 52% and 72%, respectively, in
mKO muscle compared to WT muscle (Figure 4B). Western blot ana-
lyses revealed that hexokinase II (HKII) and phosphofructokinase 1
(PFK1) protein levels were unchanged (Supplementary Figure 2F,G).
However, basal activity of pyruvate dehydrogenase (PDH) in non-172 MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH.insulin-stimulated gastrocnemius muscle was enhanced in mKO
mice compared to WT mice (Figure 4C), and phosphorylation of PDH at
S293 and S300 was decreased in clamped gastrocnemius muscle
from mKO mice compared to WT mice (Figure 4D). These results
indicate that, in response to insulin, glycolytic ﬂux downstream of PEP
is increased or that glucose is shunted into other pathways upstream
of Fru-1,6P. The level of UDP-GlcNAc was upregulated by more than
300% in mKO (Figure 4E,F) compared to WT mice, and this increase
was accompanied by a 3-fold upregulation of GFAT, which is the rate-
limiting enzyme in the hexosamine biosynthesis pathway (HBP)
(Figure 4G). Together, our data suggest that mKO muscle upregulates
activities of both glycolysis and the HBP at least in clamped mice.
However, the importance of the two pathways for glucose disposal in
basal or clamp settings cannot be quantitatively evaluated using the
available data.
Apart from changes in intracellular glucose metabolism, the metab-
olomics analysis indicated changes in fatty acid oxidation. Acetyl
carnitine level (Figure 4H) was upregulated several fold in mKO mice
compared to WT mice, so was the CoA precursor pantothenic acid
(Figure 4I), indicating that mKO mice exhibited increased capacity to
shuttle fatty acids from the cytosol into the mitochondria. This was
supported by the ﬁnding of increased Cpt1a and Cpt1b mRNA
expression (Supplementary Figure 2H), although only Cpt1a levels
were signiﬁcantly changed. In addition, we found the total level of
hormone sensitive lipase (HSL) to be unaltered, but HSL phosphory-
lation at S563, a surrogate measure of HSL activity, was signiﬁcantly
increased in mKO mice compared to WT mice (Figure 4J). Further-
more, adipose triglyceride lipase (ATGL) protein level was upregulated
by 1.75 fold in mKO mice (Figure 4K). To assess whether beta-
oxidation was altered, we measured fatty acid oxidation (FAO) in
unstimulated gastrocnemius muscle. Interestingly, while there was no
difference in complete fatty acid oxidation between WT and mKO
muscles (Figure 4L), mKO muscles contained a signiﬁcantly higher
level of acid-soluble metabolites (ASM) (Figure 4M), a hallmark of
incomplete FAO. However, mRNA levels of genes involved in FAO (i.e.,
Acadl and Acadm) were not signiﬁcantly changed (Supplementary
Figure 2H). Together, these data indicate that mKO muscle attempts
to increase fatty acid oxidation, but increased ASMs suggest that
complete oxidation of fatty acids may be impaired in skeletal muscle of
these mice.
3.6. OGT ablation alters muscle oxidative capacity
In general, slow-twitch myoﬁbers are enriched with mitochondria,
capillaries and myoglobin, and they predominately use oxidative
phosphorylation for ATP production. Fast-twitch myoﬁbers, on the
other hand, are more glycolytic and deposit greater amounts of
glycogen as an energy reserve [37e39]. To test whether OGT ablation
causes changes in muscle ﬁber type composition, and thus oxidative
capacity, we measured the expression of myosin heavy chain (MyHC) I
(Myh7), IIa (Myh2), IIx (Myh1), and IIb (Myh4) genes in the gastroc-
nemius muscle. Type I MyHC gene expression was signiﬁcantly
upregulated and type IIb MyHC gene expression was downregulated in
OGT ablated muscle (Figure 5A). Consistent with increases in Myh7
expression, the corresponding protein levels were also elevated in OGT
mKO muscles (Figure 5A, inset). Moreover, three-dimensional confocal
microscopy revealed that mKO muscle contains more mitochondria
compared to WT muscle (Figure 5B), and increased mitochondrial
content was conﬁrmed by an increased mitochondrial DNA to nuclear
DNA ratio in the gastrocnemius muscle (Figure 5B). Citrate synthase
and malate dehydrogenase activity were also higher in white part ofThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4
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the gastrocnemius muscle from mKO mice (Figure 5C,D). However,
when we measured the abundance of speciﬁc proteins in the OXPHOS
complexes, we found complex V to be increased (although not
signiﬁcantly), whereas complex I and IV were reduced signiﬁcantly in
mKO compared to WT muscle (Figure 5E). To test the function of the
mitochondria, we isolated mitochondria from gastrocnemius muscle
and measured oxygen consumption rates. We found that mitochondria
from mKO muscle have compromised respiration control ratio of state
3/state 4, indicating dysfunctional mitochondria (Figure 5F). Taken
together, we show that dysregulation of O-GlcNAcylation in skeletal
muscle drives muscle to a slower contracting, oxidative phenotype but
perhaps at the expense of properly functional mitochondria.
3.7. High-fat diets fail to induce insulin resistance in mice lacking
muscle OGT
Because mice lacking OGT in skeletal muscle are leaner, have higher
energy expenditure, and are more insulin sensitive than WT mice, we
challenged these mice with a high-fat diet (HFD) and monitored glucose
metabolism and insulin action. WT mice fed a HFD for 24 weeks gained
signiﬁcantly more weight than the HFD-fedmKOmice (Figure 6A). At the
end of HFD feeding, no differences in skeletal muscle ﬁber size were
found, whereas the IngW of mKO mice exhibited signiﬁcant browning
compared with that of WT mice (Figure 6B). In IngW, mRNA expression
of genes involved in browning was also signiﬁcantly upregulated
(Supplementary Figure 2I). In the liver of WT mice lipid accumulation
was wide-spread, whereas very little was detected in the mKO mice
(Figure 6C). Moreover, hypertrophy of pancreatic islets was evident in
the WT mice but no such obesity-induced pathology was noted in mKO
mice (Figure 6C). Consistently, blood glucose levels after a 4-h fast in
mKO mice fed 12 (Figure 6D) or 22 (Figure 6E) weeks of HFD were
signiﬁcantly lower than in WT controls. In addition, after 22 weeks on
the HFD, blood glucose levels of WT mice did not respond to 16 h of
fasting, but decreased even further in the mKO mice compared with the
4 h fast (Figure 6E). Results from glucose and insulin tolerance tests
(Figure 6FeI) showing improved glycemic control in the mKO mice,
further support the notion that dysregulation of skeletal muscle OGT
may modulate obesity-related phenotypes in other tissues to regulate
whole body insulin sensitivity.
3.8. Inducible ablation of OGT in skeletal muscle recapitulates the
mKO mouse
To exclude the possibility that the aforementioned observations were
simply a consequence of OGT-mediated defects early in development,
we generated inducible muscle-speciﬁc OGT KO (imKO) mice by
crossing ﬂoxed OGT mice with tetracycline/doxycycline inducible HSA-
cre mouse. Five-month-old adult mice were fed chow containing
doxycycline for two weeks to induce knockout of OGT in skeletal
muscle. Approximately six months after OGT ablation, we evaluated
mice with regard to muscle and fat masses, energy expenditure, and
insulin tolerance. Western blot analyses using anti-OGT and O-GlcNAc
antibodies conﬁrmed OGT ablation in skeletal muscle (Figure 7A).
imKO mice had reduced body weights after OGT ablation (Figure 7B).
Similar to mKO mice, imKO mice had normal muscle mass (Figure 7C),
reduced fat mass (Figure 7D,E) and enhanced energy expenditure
(Figure 7F). Furthermore, imKO mice were more insulin responsive
than their WT counterparts, as evidenced by glucose (Figure 7G) and
insulin (Figure 7H) tolerance tests, respectively. These data show
ablation of OGT in adult skeletal muscle recapitulates the OGT mKO
phenotype suggesting that suppression of O-GlcNAc signaling in
skeletal muscle of adult mice promotes an increase in whole body
energy metabolism and reduces adiposity.MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH. This is an open a
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Interleukin-15 production
To determine how muscle-speciﬁc knockout of OGT affects adipose
tissue, we analyzed a panel of myokines that are known to exert local
and systemic effects on adipose tissue function. Of the six myokines
selected, only Il15 and Adipoq was signiﬁcantly up-regulated in mKO
muscle (Figure 8A,B). Because circulating IL-15 has well-documented
anti-obesity effects [40], we analyzed serum IL-15 levels and found
that circulating IL-15 concentrations in mKO mice were consistently
2.5-fold higher than WT mice (Figure 8C). To investigate a potential
connection between elevated IL-15 and reduced fat mass, we used an
in vitro cell culture system in which stromal vascular fraction (SVF)
cells were cultured with muscle extracts from either WT or mKO mice
to evaluate the effect on lipid accumulation. Extracts from mKO muscle
inhibited SVF cell differentiation as evidenced by less lipid droplet
formation (Oil-Red-O staining) compared with muscle extracts from WT
mice (Figure 8D). However, this inhibition was released when an IL-15-
neutralizing antibody was introduced into the media (Figure 8D).
Furthermore, quantitative RT-PCR of the lipogenic genes revealed that
Acaca, Fasn, and Srebf1c were signiﬁcantly reduced in mKO muscle
extract-treated SVF cells (Figure 8E). These results show that muscle
from mice lacking a functional OGT in muscle produce greater levels of
circulating IL-15 that may affect adipose tissue development and
function. Our data also suggest that OGT may be directly involved in
regulating Il15 gene expression in skeletal muscle.
At the molecular level, OGT has been shown to repress gene
expression epigenetically. It was shown that O-GlcNAcylation stabilizes
histone methyltransferase enhancer of zeste homolog 2 (EZH2), which
facilitates the formation of the trimethylation of histone 3 at lysine 27
(H3K27me3) thereby repressing gene expression in human MCF-7
cells [41]. To explore the possible existence of a similar mechanism
in skeletal muscle, we used co-immunoprecipitation (Co-IP) to study
the interaction of OGT and EZH2. Co-IP results revealed that OGT can
O-GlcNAcylate EZH2 in skeletal muscle (Figure 8F). To assess whether
the OGT and EZH2 interaction has any relevance to Il15 gene regu-
lation, we conducted a chromatin immunoprecipitation (ChIP) assay. O-
GlcNAc, EZH2, and H3K27me3 were all enriched at the Il15 promoter
region (Figure 8GeI). These ﬁndings suggest the existence of the OGT-
EZH2-H3K27me3 axis in skeletal muscle, similar to the mechanism
responsible for controlling gene repression in a human adenocarci-
noma cell line. These results indicate that the increases in circulating
IL-15 we observed in mKO mice are likely mediated by epigenetic
regulation of the Il15 gene locus.
4. DISCUSSION
Despite its discovery three decades ago, the physiological signiﬁcance
of O-GlcNAcylation as a nutrient sensor has only recently been
recognized [42]. O-GlcNAc is a dynamic posttranslational modiﬁcation
that is targeted to Ser/Thr residues by O-GlcNAc transferase (OGT) and
removed by O-GlcNAcase (OGA). The substrate for OGT is UDP-GlcNAc,
a product of the hexosamine biosynthetic pathway (HBP). UDP-GlcNAc
is an ideal gauge of metabolic status because levels reﬂect ﬂuxes
through a number of metabolic pathways, especially carbohydrate
metabolism. Based on our ﬁnding that O-GlcNAcylation levels were
elevated in skeletal muscle from T2D people, we hypothesized that
OGT may be important for nutrient sensing in this tissue and for whole
body insulin sensitivity. Data presented herein clearly demonstrate that
skeletal muscle OGT is centrally important for maintaining muscle
energy homeostasis, mitochondrial function, and insulin sentivity.
Moreover, we show that Il15 gene transcription is epigeneticallyccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 173
Original Articlecontrolled by OGT. Thus, given the role of IL-15 in exogenous lipid
partitioning [43], OGT in skeletal muscle is important not only for the
ability to survey cellular nutrient status but also for regulation of
substrate availability.
OGT mKO mice were markedly more insulin sensitive compared with
WT controls. In vivo studies involving manipulation of the HBP support
this ﬁnding. Mice that transgenically overexpress GFAT in GLUT4
expressing tissues show an opposite phenotype with decreased whole
body insulin sensitivity measured using the hyperinsulinimic eugly-
cemic clamp technique [44]. Likewise, if OGT is overexpressed using a
similar approach, whole body insulin sensitivity is also decreased, and
mice display hyperinsulinemia [22]. Thus, manipulation of ﬂux through
the HBP appears to affect insulin action, and the HBP could serve as a
potential pharmacological target. Interestingly, not all muscle types
from the OGT mKO mice showed enhanced glucose uptake in response
to insulin compared with WT littermates. We have only analyzed the
gastrocnemius muscle from the clamp experiment; therefore, we are
not currently able to explain these muscle type differences. However, it
was recently shown that IL-15 activates the JAK3/STAT3 pathway in
skeletal muscle cells, and this induces glucose uptake [45]. Therefore,
we speculate that the responsiveness to IL-15 may be different be-
tween muscle types in OGT mKO mice. Further studies are necessary
to address this intriguing observation.
Based on PDH activity and the level of glycolytic intermediates in the
gastrocnemius muscle in response to insulin, knockout of OGT appears
to alter glycolytic ﬂux. Overexpression of OGT in SY5Y cells decreases
glycolysis [46], and several proteins within the glycolytic pathway are
known to be O-GlcNAcylated in rat skeletal muscle [47] and in HEK293
cells [48]. Thus, our data are in line with the idea that OGT may act as a
mediator of this pathway. Moreover, since manipulation of O-GlcNAc
signaling affects mitochondrial function and dynamics in cardiac
myocytes [49], in muscle cells in vitro [50], and in skeletal muscle (the
present study), it is conceivable that changes in glycolytic ﬂux can be
explained in part by changes in the capacity or efﬁciency for ATP
generation by oxidative phosphorylation.
Lack of discernable histological and functional anomalies in skeletal
muscle of OGT mKO mice argues that OGT may not be requisite for
normal muscle function. This is somewhat surprising given the widely
abundant nature of O-GlcNAcylation on structural muscle proteins [1].
However, the idea that O-GlcNAcylation is a part of a complex nutrient-
sensing pathway, whereby protein O-GlcNAcylation serves as a niche-
based nutrient sentinel for cells, remains intriguing especially from a
whole organismal vantage point. Indeed, surveying nutrient availability
is important in times of both nutrient plenty and scarcity. Nutrient
availability is one of the most effective means of controlling epigenetic
events [10]. We show that Il15 expression is a consequence of OGT
ablation in skeletal muscle. Speciﬁcally, we observed nearly a 5-fold
increase in skeletal muscle Il15 mRNA expression, which resulted in
a corresponding increase in circulating levels of IL-15 in mKO mice.
Given that O-GlcNAcylation parallels nutrient availability in cells [51,52]
and that chromatin is a major site of O-GlcNAcylation [53e56], we
hypothesized that OGT plays a role in the epigenetic regulation of Il15
gene expression [10,57]. Indeed, OGT O-GlcNAcylates EZH2, a key part
of the polycomb repressive complex 2 (PRC2), which may repress Il15
expression through H3K27me3 modiﬁcations [10]. Using co-
immunoprecipitation and chromatin immunoprecipitation assays, we
found that OGT, EZH2, and H3K27me3 localize to Il15 promoter se-
quences and that the increase in muscle-speciﬁc IL-15 production is, in
part, due to epigenetic modiﬁcation of the promoter. Moreover, our data
are clearly in line with the repressive effect of OGT on Il15 expression in
muscle. We cannot exclude the possibility that OGT ablation results in174 MOLECULAR METABOLISM 11 (2018) 160e177  2018 The Authors. Published by Elsevier GmbH.other yet unknown skeletal muscle permutation(s) that may directly or
indirectly disrupt other cellular pathways that increase muscle energy
expenditure and lead to a leaner phenotype. Nor can we rule out other
molecular ‘insults’ that may drive increases in cytokine production [58]
in our KO mice. Even so, muscle-derived IL-15 production increases in
response to a whole-body energy imbalance [59] and may in part
explain a number of the characteristics displayed in mice lacking
effective O-GlcNAc signaling events in skeletal muscle.
IL15 is highly expressed in human skeletal muscle tissue compared to
most other tissues of the body [60] suggesting a critical role for the
growth and maintenance of skeletal muscle. Recent studies show that
IL-15 have little effect on skeletal muscle accretion [61,62] and raise
the possibility that IL-15 acts as a means to elicit responses in distal
whole body repositories as a means of mobilizing energy substrates to
support its needs. Indeed, IL-15 is now known as a myokine that
targets remote tissues to liberate energy resources [63]. Furthermore,
prolonged stimulation of muscle by IL-15 increases Ppargc1a, Sirt1,
and Ucp2 expression, all highly indicative of the conversion of skeletal
muscle to a more oxidative phenotype [64]. Congruent with this, OGT
mKO mice were indeed more oxidative than WT mice as evidenced by
greater mitochondrial DNA and enzyme contents and greater amounts
of type I myosin heavy chain isoform. These data argue that OGT mKO
mice have greater capacity to oxidize energy substrates, which is in
line with calorimetry estimates showing that these mice exhibit greater
energy expenditure regardless of the time-of-day studied.
Despite many similarities between the Il15 transgenic model [64] and
the OGT mKO model, they differ on key aspects. OGT mKO mice were
more sedentary than controls, which differs from mice over-expressing
Il15 [64]. Whether the increase in body temperature affects the desire
to move or whether loss of OGT in tissues somehow keeps animals
from moving requires additional attention. Even so, both models show
increases in markers indicative of enhanced oxidative capacity.
Despite this, OGT mKO mice have higher utilization of glucose relative
to fatty acids as evidenced by the higher RER. Increased energy
expenditure in combination with impaired mitochondrial function may
account for this phenotype, and our current thinking is that lack of OGT
may increase oxidative capacity but may also result in mitochondrial
insults rendering the mitochondrial machinery impaired.
Mice lacking functional OGT were smaller than their WT littermates.
However, this reduction in weight was not due to decreased muscle
mass but rather a 50% reduction in adipose tissue weight. Curiously,
mice receiving exogenous IL-15 experience similar reductions in
whole-body adiposity without reductions in food intake [65e67]. This
is also observed in rats administered recombinant IL-15 and mice
overexpressing an Il15 transgene [62,64,68]. Conversely, those mice
lacking a functional Il15 gene are obese [69]. Fat cells of OGT mKO
mice were also smaller suggesting OGT ablation in skeletal muscle
altered lipogenesis and lipolysis in adipose tissue, two well-known IL-
15 functions [66,70]. Additionally, inguinal white adipose tissue con-
tained greater levels of UCP1 protein and many browning marker
genes were also upregulated. These data suggest up-regulation of
muscle IL-15 in response to OGT ablation in skeletal muscle may be
responsible for a leaner phenotype, perhaps by partitioning substrates
away from adipose tissue and/or increasing energy expenditure in
skeletal muscle. To address this thesis further, we subjected mKO
mice to a high-fat diet to induce obesity [71]. As expected, over-fed
mKO mice were leaner and had improved blood glucose levels
compared to WT controls suggesting ablation of OGT in skeletal muscle
altered whole body glucose tolerance. These ﬁndings supported our
thesis, as those mice over-expressing IL-15 are also protected from
this type of induced obesity [62]. Even so, however, discrepanciesThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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between Il15 overexpressing mice and OGT mKO mice are not sur-
prising given the magnitude of increases observed in overexpressing
models and the fact that OGT ablation likely impacts the function of
many cytosolic, nuclear, and mitochondrial proteins [48].
In preparation of this manuscript, two studies were published on the
role of OGT in skeletal muscle using skeletal muscle-speciﬁc OGT KO
mice. In one study, no differences in glucose metabolism were
observed between OGT KO and WT [72]. However, animals used were
10e12 weeks of age, and, as our data show that the phenotype of
muscle-speciﬁc OGT KO mice develops from 12 weeks of age, we
believe that the authors simply missed the phenotype of the mice in
that study. This was conﬁrmed in a follow-up study performed by the
same authors in which muscle-speciﬁc OGT KO mice were studied at
older age [73]. In that study, the observed phenotype of the OGT KO
mice corroborated our ﬁndings of enhanced energy expenditure,
improved whole body insulin sensitivity, and the resistance to obesity
in response to HFD feeding.
In summary, results of the present study demonstrate a role of OGT in
the maintenance of skeletal muscle energy metabolism and whole-
body metabolic homeostasis. Lack of OGT results in increased whole
body energy expenditure, altered muscle substrate utilization, and loss
in the ability of muscle cells to regulate Il15 expression. Consequences
of increased plasma IL-15 levels likely include changes in the ability to
store and metabolize energy substrates, which improves whole-body
insulin sensitivity and enhances resistance to obesity. From an
evolutionary viewpoint, it makes sense for animals to have a mecha-
nism in place that regulates partitioning of substrates from energy
stores. For instance, during fasting, ﬂux through the HBP would be
reduced. Consequently, UDP-GlcNAc levels would be lowered, which
would result in diminished OGT activity. In turn, the inhibitory effects on
Il15 expression would be released, allowing an elevation in circulating
levels of IL-15, which would promote mobilization of lipids from adi-
pose depots. Further studies are needed to fully understand how other
whole body and tissue-speciﬁc functions are impacted by OGT ablation
in muscle. Moreover, additional work is required to dissect more
precisely the differences observed between mKO mice and models in
which circulating IL-15 levels are elevated.
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